This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Renal disease				
End-stage renal disease (ESRD)	Plasminogen activator urokinase receptor (PLAUR; uPAR; suPAR)	<p>A study in mice and in patient samples suggests decreasing serum levels of uPAR could help prevent ESRD in kidney transplant patients. Serum from patients with ESRD-associated focal segmental glomerulosclerosis (FSGS) had higher uPAR levels than serum from healthy controls. In a mouse model of FSGS, mAbs against uPAR decreased disease symptoms compared with IgG control. Next steps include developing an immunoadsorption column for removing soluble uPAR from human serum.</p> <p>SciBX 4(32); doi:10.1038/scibx.2011.913 Published online Aug. 18, 2011</p>	Covered by patent applications and issued patents; available for licensing	<p>Wei, C. <i>et al. Nat. Med.</i>; published online July 31, 2011; doi:10.1038/nm.2411</p> <p>Contact: Jochen Reiser, University of Miami, Miami, Fla. e-mail: jreiser@med.miami.edu</p>